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doses to the right coronary artery (0.4-35Gy). Analyses of 
cardiac doses for the 10 randomly selected CT scans showed 
considerable inter-patient dose variation for left tangential 
radiotherapy but less variability for left direct beams. 
Conclusions: Doses to cardiac structures varied considerably 
depending on the regimen used. These doses can be used to 
assess which parts of the heart generally received higher 
doses relative to other parts of the heart. For example, left 
sided tangential radiotherapy tended to give higher doses to 
the apex compared with the other ventricular segments. Left 
sided regimens tended to deliver high radiation doses to the 
left anterior descending coronary artery, and right-sided 
regimens tended to deliver high doses to the right coronary 
artery. 
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Purpose/Objective: Neo-adjuvant radiation in rectal cancer 
improves R0 resection rates and reduces local relapse. ESMO 
and UK National Institute of Clinical Excellence (NICE) 
guidance advocate consideration of short course radiotherapy 
(SCRT) or long course chemoradiotherapy (CRT) for 
intermediate risk rectal cancer and CRT for high risk 
tumours. However the Mercury group suggests only selected 
high risk tumours require neo-adjuvant CRT. As such there 
remains controversy regarding patient selection for radiation, 
with significant variations in current practise. Our use of 
radiotherapy over a 5-year period has mirrored Mercury 
guidance; we aim to assess the application of this guidance in 
a routine clinical setting. 
Materials and Methods: A retrospective analysis was 
performed, at a single tertiary referral centre, of patients 
receiving radical surgery for primary rectal cancer from 2007 
to 2012. Using multiple hospital electronic data-bases, we 
collected patient demographics, radiological TNM stage and 
CRM status, radiation delivered, pathological presence of 
extra mural vascular invasion (EMVI), R1 resection and local 
relapse rates. Risk stratification was based on the NICE 
criteria. 
Results: A total of 275 patients were identified. Of these, the 
proportion with T1, T2, T3 and T4 tumours was 12%, 17%, 58% 
and 13% respectively. The percentage of patients with N0, N1 
and N2 was 52%, 30% and 18% respectively. 1% of patients had 
low volume metastatic disease. 40% had threatened/involved 
CRM and 29% of the tumours had EMVI. Only 5% of the 
patients had R1 resection.The proportion with low, 
intermediate and high risk were 18%, 42% and 40% 
respectively. No patient received SCRT. 82% of the high risk 
patients and only 8% of intermediate risk received long 
course CRT.Median follow up was 54months (range 15 to 
60mths). 4 patients had synchronous metastases and hence 
were excluded from follow up. Of the remaining 271 
patients, the rate of local and distant recurrence was 2% and 
20% respectively. In the intermediate risk group, the R0 rate 
was 97% and the local relapse rate was 1.7%. 
Figure 1 depicts the proportion of patients receiving long 





Conclusions:This data concurs with the Mercury guidance 
that only selected high risk rectal cancer patients require 
CRT. Over a 5 year period despite the increasingly narrowed 
selection of patients for CRT we have maintained a local 
relapse rate of 2-5%.The intermediate risk group had 
acceptable R0 resection and local relapse rates; therefore we 
would suggest that there is no role for SCRT in rectal 
cancer.Lastly, due to the significant rate of distant relapse, 
our data concurs with current plans to investigate the role of 
neo-adjuvant chemotherapy in rectal cancer.  
   
 
 
 
